公开(公告)号：US20240082162A1

公开(公告)日：2024-03-14

申请号：US17928278

申请日：2021-05-25

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K31/4178

CPC分类号： A61K9/2054 ,  A61K9/0053 ,  A61K31/4178

摘要： The present invention relates to a pharmaceutical formulations and compositions comprising cholinergic agonist agents such as pilocarpine-R-(+)-lipoate or its salt, solvate, or hydrate thereof for oral administration with improved compliance, safety, and bioavailability. It further discloses methods of preparing the formulations and its use for the treatment of xerostomia, dry mouth and Sjogren's syndrome.

公开(公告)号：US20230310391A1

公开(公告)日：2023-10-05

申请号：US17993868

申请日：2022-11-23

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： A61K31/439 ,  A61K31/223 ,  A61K31/385 ,  A61K31/4178 ,  A61K9/00

CPC分类号： A61K31/439 ,  A61K31/223 ,  A61K31/385 ,  A61K31/4178 ,  A61K9/0048 ,  A61K9/0053

摘要： The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof. The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid.

公开(公告)号：US20220324813A1

公开(公告)日：2022-10-13

申请号：US17631763

申请日：2020-07-16

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： C07D233/08 ,  C07D409/12

摘要： The present invention relates to compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers, prodrugs, hydrates and or derivatives thereof. The Pharmaceutical composition comprises an effective amount of compounds of formula I, formula II, formula III, formula IV, Formula V, formula VI or formula VII and the methods of using the composition for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermal administration, spray, injection or other known formulation in the art.

公开(公告)号：US20220233504A1

公开(公告)日：2022-07-28

申请号：US17488241

申请日：2021-09-28

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： A61K31/4045 ,  A61K31/167 ,  A61K9/00 ,  A61K47/14

摘要： The present disclosure provides a pharmaceutical composition comprising Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of mucositis, oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral and gastrointestinal disease/conditions using the advantageous compositions of the present disclosure.

公开(公告)号：US11312707B2

公开(公告)日：2022-04-26

申请号：US16464377

申请日：2017-11-24

申请人： CELLIX BIO PRIVATE LIMITED

发明人： Mahesh Kandula

IPC分类号： A61P1/02 ,  C07C211/03 ,  C07C211/21 ,  C07D233/64 ,  C07D405/14 ,  C07D233/60 ,  C07D233/62 ,  C07D239/22 ,  C07D403/06

摘要： The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

公开(公告)号：US20210188817A1

公开(公告)日：2021-06-24

申请号：US17250756

申请日：2019-07-09

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： C07D403/12 ,  C07D339/04 ,  C07D213/46 ,  C07C63/36 ,  C07C229/42 ,  C07C57/12 ,  C07C237/26 ,  A61P31/04

摘要： The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V and formula VI and the methods for the treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.

公开(公告)号：US10933052B2

公开(公告)日：2021-03-02

申请号：US16790492

申请日：2020-02-13

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： A61K31/4178 ,  A61K31/385 ,  A61K9/00 ,  A61P27/06

摘要： Aspects of the present disclosure provide compound of Formula I and pharmaceutically acceptable hydrates, solvates, crystals, co-crystals, enantiomers, stereoisomers, polymorphs and prodrugs thereof that can find utility in treatment of eye disorders and complications associated therewith. Aspects of the present disclosure also relate to methods of treating an eye disorder and/or complications thereof in a subject in need thereof by administering the compound of Formula I or a pharmaceutically acceptable hydrate, solvate, crystal, enantiomer, stereoisomer, polymorph or prodrug thereof. wherein, X+ represents,

公开(公告)号：US10829454B2

公开(公告)日：2020-11-10

申请号：US15755729

申请日：2016-09-02

申请人： CELLIXBIO PRIVATE LIMITED

发明人： Mahesh Kandula

IPC分类号： A61K31/165 ,  A61K31/164 ,  A61K31/15 ,  C07C233/49 ,  C07C243/30 ,  A61P9/12 ,  A61P25/16 ,  C07D221/18

摘要： The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.

公开(公告)号：US20190177267A1

公开(公告)日：2019-06-13

申请号：US16323069

申请日：2017-04-19

申请人： CELLIX BIO PRIVATE LIMITED

发明人： Mahesh Kandula

IPC分类号： C07C233/55 ,  C07C229/60 ,  A61P1/06 ,  A61P29/00

摘要： The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

公开(公告)号：US09738631B2

公开(公告)日：2017-08-22

申请号：US14533113

申请日：2013-01-28

申请人： CELLIXBIO PRIVATE LIMITED

发明人： Mahesh Kandula

IPC分类号： A61K31/55 ,  C07D223/28 ,  C07D401/12 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D495/04 ,  A61K45/06 ,  A61K47/48

CPC分类号： C07D409/12 ,  A61K31/55 ,  A61K45/06 ,  A61K47/543 ,  A61K47/55 ,  C07D223/28

摘要： The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.